Evidence map›Paper›PMID 33776384›Full record

ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2021

First In Class (

David Mingle, Meirambek Ospanov, Mohamed O Radwan, Nicole Ashpole, Masami Otsuka, Samir A Ross, Larry Walker, Abbas G Shilabin, Mohamed A Ibrahim

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. ACS omega · 2022
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

David MingleDepartment of Chemistry, East Tennessee State University, Johnson City, TN 37614, USA.
Meirambek OspanovNational Center for Natural Products Research, University of Mississippi, University, MS 38677.
Mohamed O RadwanMedicinal and Biological Chemistry Science Farm Joint Research Laboratory, Kumamoto University, Kumamoto 862-0973, Japan.
Nicole AshpoleDepartment of BioMolecular Sciences, University of Mississippi, University, MS 38677.
Masami OtsukaMedicinal and Biological Chemistry Science Farm Joint Research Laboratory, Kumamoto University, Kumamoto 862-0973, Japan.
Samir A RossNational Center for Natural Products Research, University of Mississippi, University, MS 38677.
Larry WalkerNational Center for Natural Products Research, University of Mississippi, University, MS 38677.
Abbas G ShilabinDepartment of Chemistry, East Tennessee State University, Johnson City, TN 37614, USA.
Mohamed A IbrahimNational Center for Natural Products Research, University of Mississippi, University, MS 38677.
University of Mississippi · USEast Tennessee State University · USKumamoto University · JPNational Research Centre · EG

Funding

Pilot Project ProgramP30GM122733 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI MAJUMDAR, SOUMYAJIT · 2018 to 2022
$5.3M
NIGMS NIH HHS P30 GM122733
6 · The paper itself

Abstract

Newly designed pyrrolo[2,1-c][1,4]benzodiazepines tricyclic skeleton has shown potential clusters of cannabinoid receptors CB1/CB2 selective ligands. CB2 plays a critical role in microglial-derived neuroinflammation, where it modulates cell proliferation, migration, and differentiation into M1 or M2 phenotypes. Beginning with computer-based docking studies accounting the recently discovered X-ray crystal structure of CB2, we designed a series of PBD analogs as potential ligands of CB2 and tested their binding affinities. Interestingly, computational studies and theoretical binding affinities of several selected (

Indexed as

Cannabinoid receptors CB1/CB2central nervous system (CNS)neurodegenerative diseasesneuroinflammationpyrrolobenzodiazepines

Identifiers

PMID33776384
PMCPMC7992105
OpenAlexW3090485007

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.